Travena, Inc. (TRVN) stock prices were down 3.24% shortly after market trading commenced on July 27th, 2021, bringing the price per share down to USD$1.3464.
First Patient Enrolment
July 26th, 2021 saw TRVN stock announce the enrollment of its first patient in the ACTIV-4 Host Tissue (Accelerating Covid-19 Therapeutic Interventions and Vaccines) trial. With the end of Covid-19 requiring a multi-pronged solution, TRVN stock is excited to be developing TRV027 as a pioneering active treatment arm available for patient randomization.
ACTIV-4 Host Tissue Trial
The ACTIV-4 Host Tissue trial serves to evaluate four investigational agents that fight dysregulation of the renin-angiotensin-aldosterone system (RAAS) and immune system irregularities caused by Covid-19 infections. The treatment is a novel AT1 receptor selective agonist that targets the AT1 receptor to bind to within the RAAS, thereby obstructing the damaging pathway that results in acute lung damage and abnormal blood clotting. TRVN stock’s treatment activates the cellular pathway that selectively targets reparative actions that improve lung function and promote anti-inflammatory effects.
TRVN Stock’s Efforts Against Pandemic
More than 1600 patients will be enrolled across 50 sites spanning the United States for the TRVN stock’s trial. TRV027 is part of the initial trial launch, with additional study arms being added to the trial over time. The study will serve to evaluate the impact of each intervention on recovery, supplemental oxygen use, need for mechanical ventilation, organ failure, and mortality. As the global Covid-19 pandemic continues to devastate the globe, the development of interventions remains a top priority, aiming to combat the vascular, fibrotic, and inflammatory damage done by the virus.
About the Trial
The ACTIV-4 Host Tissue is a multi-site, randomized, placebo-controlled clinical trial with multiple treatment arms. Each arm is expected to enroll roughly 300-400 Covid-19 patients that are 18 years of age or older. The four trial arms will test investigational agents that target the RAAS or immune system through distinct mechanisms of action. The trial is designed for TRVN stock to determine whether modulation of these systems is a viable solution to preventing progression to critical illness in hospitalized Covid-19 patients.
Future Outlook for TRVN Stock
Armed with the initiation of patient testing in its ACTIV-4 Host Tissue trial, TRVN stock is poised to capitalize on the opportunities afforded to it. The company is keen to leverage the resources at its disposal to usher in significant long-term growth, which investors hope will translate into gains in shareholder value.
